clinical trial · NCT07126990
Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma
Xiaorong Wu·phase2·enrolling by invitation·n = 40
GliomaNovel oncolytic virus Ad-TD-nsIL12
brief summary
Clinical study of a novel oncolytic virus Ad-TD-nsIL12 in the treatment of primary high-grade glioma
started
Feb 12, 2025
primary completion
Aug 30, 2028
completion
Aug 30, 2028
last updated
Mar 23, 2026
detailed description
This study will conduct two prospective, single-arm, single-center, exploratory clinical trials aimed at assessing the preliminary efficacy and safety of the novel oncolytic adenovirus Ad-TD-nsIL12 in treating primary HGG. Trial 1 will preliminarily evaluate the efficacy and safety of Ad-TD-nsIL12 as neoadjuvant treatment for patients with non-functional zone primary HGG; Trial 2 will preliminarily evaluate the efficacy and safety of Ad-TD-nsIL12 in treating patients with functional zone and thalamic primary HGG, as well as their quality of life.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol